Definium Therapeutics, Inc. Definium Therapeutics, Inc.

Definium Therapeutics, Inc.

DFTX

Classifica tra le azioni #3750
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm... Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Prezzo delle azioni
$33.26
Ultima sincronizzazione: 2026-10-19
Capitalizzazione di mercato
$4.47B
Variazione (1 giorno)
3.60%
Variazione (1 anno)
204.10%
Paese
US
Scambia Definium Therapeutics, Inc. (DFTX)

Categoria

Healthcare
Storico del rendimento da dividendi per Definium Therapeutics, Inc. (DFTX)
Il rendimento da dividendi (TTM) di Definium Therapeutics, Inc. (simbolo azionario: DFTX) al 2026 è: 0
Rendimento medio negli ultimi 5 anni: 0.00%
Storico del rendimento da dividendi per Definium Therapeutics, Inc. (DFTX) da 2026 a 2026
Rendimento da dividendi alla fine di ogni anno (TTM)
Anno Rendimento da dividendi Cambia
Non abbastanza dati per le date fornite.
Rendimenti da dividendi (TTM) di aziende simili o concorrenti
Azienda Rendimento da dividendi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.17%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL